ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

ARLINGTON, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA) (“KALA” or the “Company”), today announced the closing of its previously announced registered direct offering priced at ...

Securities and Exchange Commission filings indicate that Oxford Finance LLC acquired 1.62 million common shares, representing 16.5% ownership in the clinical-stage company. Oxford Finance, the ...

Kala Bio focuses on developing therapies for rare and severe diseases of the eye using its proprietary mesenchymal stem cell secretome platform. Its lead product candidate, KPI-012, had previously ...

Investing.com -- Kala Pharmaceuticals Inc (NASDAQ:KALA) stock dropped 6.7% Friday after the company announced the closing of its previously announced registered direct offering that raised ...

The latest price target for Kala Bio (NASDAQ:KALA) was reported by HC Wainwright & Co. on September 29, 2025. The analyst firm set a price target for $0.00 expecting KALA to fall to within 12 months ...

One of the most classic and revered stories of all time, Edgar Rice Burroughs' Tarzan returns to the big screen for a new generation. Tarzan and Jane face a mercenary army dispatched by the evil CEO ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...